A detailed history of Parallax Volatility Advisers, L.P. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Parallax Volatility Advisers, L.P. holds 149,000 shares of APLS stock, worth $4.46 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
149,000
Holding current value
$4.46 Million
% of portfolio
0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$37.14 - $64.82 $1.46 Million - $2.55 Million
39,392 New
39,392 $2.36 Million
Q1 2023

May 15, 2023

SELL
$46.59 - $66.96 $1.48 Million - $2.13 Million
-31,791 Reduced 99.72%
89 $5,000
Q4 2022

Feb 14, 2023

SELL
$43.24 - $61.04 $1.96 Million - $2.76 Million
-45,273 Reduced 58.68%
31,880 $1.65 Million
Q3 2022

Nov 14, 2022

BUY
$44.76 - $69.66 $1.3 Million - $2.03 Million
29,090 Added 60.52%
77,153 $5.27 Million
Q2 2022

Aug 15, 2022

BUY
$35.07 - $59.21 $1.69 Million - $2.85 Million
48,053 Added 480530.0%
48,063 $2.17 Million
Q1 2022

May 16, 2022

SELL
$35.46 - $54.12 $387,435 - $591,315
-10,926 Reduced 99.91%
10 $1,000
Q4 2021

Feb 14, 2022

BUY
$30.74 - $49.16 $334,820 - $535,450
10,892 Added 24754.55%
10,936 $517,000
Q3 2021

Nov 15, 2021

SELL
$31.4 - $69.84 $1.46 Million - $3.24 Million
-46,370 Reduced 99.91%
44 $1,000
Q2 2021

Aug 16, 2021

BUY
$40.9 - $64.9 $1.9 Million - $3.01 Million
46,414 New
46,414 $2.93 Million
Q3 2020

Nov 13, 2020

SELL
$25.89 - $33.65 $10,174 - $13,224
-393 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$24.8 - $38.49 $347,274 - $538,975
-14,003 Reduced 97.27%
393 $13,000
Q1 2020

May 15, 2020

BUY
$17.91 - $44.33 $217,642 - $538,698
12,152 Added 541.53%
14,396 $386,000
Q4 2019

Feb 14, 2020

BUY
$22.1 - $30.8 $49,592 - $69,115
2,244 New
2,244 $69,000
Q1 2018

May 15, 2018

SELL
$14.01 - $26.02 $23,536 - $43,713
-1,680 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$12.71 - $21.7 $21,352 - $36,456
1,680
1,680 $36,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.29B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Parallax Volatility Advisers, L.P. Portfolio

Follow Parallax Volatility Advisers, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.